7.30
1.25%
0.09
Biocryst Pharmaceuticals Inc stock is traded at $7.30, with a volume of 1.58M.
It is up +1.25% in the last 24 hours and down -4.20% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$7.21
Open:
$7.16
24h Volume:
1.58M
Relative Volume:
0.83
Market Cap:
$1.51B
Revenue:
$331.41M
Net Income/Loss:
$-226.54M
P/E Ratio:
-5.84
EPS:
-1.25
Net Cash Flow:
$-97.31M
1W Performance:
-4.45%
1M Performance:
-4.20%
6M Performance:
+19.09%
1Y Performance:
+35.19%
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Industry
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
BCRX | 7.30 | 1.51B | 331.41M | -226.54M | -97.31M | -1.25 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
Feb-22-23 | Upgrade | Needham | Hold → Buy |
Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
Dec-10-21 | Initiated | Oppenheimer | Outperform |
Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
Mar-01-21 | Initiated | Cowen | Outperform |
Sep-29-20 | Resumed | JP Morgan | Overweight |
Jun-17-20 | Initiated | BTIG Research | Neutral |
May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-16-18 | Resumed | Piper Jaffray | Overweight |
Aug-08-18 | Resumed | JP Morgan | Overweight |
Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Dec-20-17 | Initiated | Barclays | Equal Weight |
Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Feb-09-16 | Reiterated | FBR Capital | Outperform |
Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
Cystinosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Counterweight Ventures LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Primary Hyperoxaluria Drug Market SWOT Analysis by Leading Key Players: Pfizer, Novartis, BioCryst - openPR
Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 7.5% - MarketBeat
BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewswire
BioCryst's ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland | BCRX Stock News - StockTitan
(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Avian influenza Treatment Market Growth Trends: Regional - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com
HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings - MarketBeat
Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights
Objective long/short (BCRX) Report - Stock Traders Daily
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst (BCRX) to Present at Three Major Healthcare Investor Conferences | BCRX Stock News - StockTitan
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates - MarketBeat
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth - Investing.com India
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call Transcript - Insider Monkey
BioCryst Announces Strong Q3 2024 Revenue Growth - Yahoo Finance
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 - Marketscreener.com
BioCryst Awards Key Talent with $8.01 Stock Options, RSU Compensation Package | BCRX Stock News - StockTitan
BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highli - GuruFocus.com
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth By Investing.com - Investing.com Australia
BioCryst: Q3 Earnings Snapshot - Darien Times
BioCryst shares hold Buy rating, BofA sees entry point By Investing.com - Investing.com Canada
Piper Sandler lifts BioCryst Pharma target to $21 on Q3 beat - Investing.com UK
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript - AOL
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap DownHere's Why - MarketBeat
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
BioCryst Pharmaceuticals Q3 2024 Earnings: EPS Loss of $0.07, Re - GuruFocus.com
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
BioCryst Pharmaceuticals Q3 2024 Earnings Preview - MSN
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Rice Hall James & Associates LLC - MarketBeat
‘Breakthrough’ quarter for Island Pharmaceuticals - The Mercury
Island Pharmaceuticals enjoys big quarter - Courier Mail
Semanteon Capital Management LP Invests $1.14 Million in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on Monday - MarketBeat
When (BCRX) Moves Investors should Listen - Stock Traders Daily
How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% - MSN
What's Going On With BioCryst Pharmaceuticals Stock? - MSN
BioCryst Presents New Real-World Evidence Showing High - GlobeNewswire
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat) - StockTitan
High Growth Tech Stocks To Watch In October 2024 - Simply Wall St
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):